Extra proxy material
Open the filing on sec.gov
NRX Pharmaceuticals, Inc. (NRXP)
Nasdaq: NRXP · Pharmaceutical Preparations · Wilmington, DE · filing with the SEC since 2017
The companyfiscal 2025, as filed
Revenue$1.4M
Net income-$28.6M-13.9%
Earnings per share$-1.34+43.2%
Operating cash flow-$14.1M-32.7%
Cash$7.8M+440.3%
Debtn/a
Shareholders’ equity-$15.9M+31.4%
Shares, diluted21.4M+101.1%
Return on equityn/a
The recordfrom its filings
Filings in 202633
Newest filingNov 5 · DEFA14A
Annual reportMar 23, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $3.6MNet income -$23.5MCash from operations -$19.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Proxy statement
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.